Bristol-Myers Squibb's Cobenfy launch shows strong initial sales and broad Medicaid/Medicare coverage, supporting its blockbuster potential in schizophrenia and future label expansions.

The US regulator has cleared the combination of muscarinic M1 and M4 agonist xanomeline tartrate and muscarinic antagonist trospium chloride – formerly known as KarXT – under the Cobenfy brand ...

We include ourselves in that category. Thankfully, Nebulr thought of us and created the Default Dark Mode texture pack for Minecraft, making the light gray interface a much nicer dark gray that ...

We’re all secretly hoping it won’t happen every time we press the starter button ... back on the road in a jiffy – a motorcycle jump pack. These work like an extension to your bike ...

Pavone discusses how these methods can be used to combat a lack of diversity in clinical trials. While challenges remain, AI is accelerating the process by enabling researchers to identify and design ...

Research suggests that a new type of antipsychotic, xanomeline and trospium chloride (Cobenfy), is associated with significant improvements in cognitive symptoms among people with schizophrenia.

3) Bristol Myers Squibb's Cobenfy (KarXT; xanomeline and trospium chloride), a dual M1/M4 muscarinic acetylcholine receptor agonist for schizophrenia and psychosis related to Alzheimer's disease.

February 10, 2025 • Elon Musk's Department of Government Efficiency is quickly expanding its reach through the federal government. January 25, 2025 • A Food and Drug Administration project to ...

Royalty Pharma to provide R&D investment of up to $250 million for Biogen’s litifilimab, a potential first-in-class biologic in Phase 3 development for the treatment of lupusNEW YORK, Feb. 12 ...

After hours: February 13 at 6:00:43 PM EST Loading Chart for PACK ...

The state’s life sciences industry honored its own last Thursday night at BioNJ’s annual Dinner Meeting & Innovation Celebration. Held at the Hilton East Brunswick, the gala represented a who’s who of ...